|
 It is the first country to disclose a timeline for talks with
Gilead. The drugmaker said this week it has priced remdesivir at
$390 per vial in developed countries and agreed to allocate nearly
all of its supply of the drug to the United States over the next
three months.
One of the few treatments shown to alter the course of COVID-19,
remdesivir is expected to be in high demand. The intravenously
administered medicine has won emergency-use authorisation in several
countries and full approval in Japan after a clinical trial showed
it helped shorten hospital stays.
Only patients severely ill with COVID-19 are eligible for remdesivir
and South Korea currently has 33 such patients, the Korea Centers
for Disease Control and Prevention (KCDC) said.
KCDC director Jeong Eun-kyeong told a briefing that patients who
developed symptoms in less than 10 days and were suffering from
pneumonia and a shortage of oxygen would be considered eligible. A
domestic panel of experts has found that anti-viral drugs like
remdesivir are more effective if given in the early stages of the
disease, she added.
[to top of second column] |
The KCDC did not disclose how many doses have been donated by the U.S. firm.
South Korea will consider whether remdesivir should be covered by national
health insurance after the purchase negotiations in August, said Jeong.
Based on current treatment patterns, a course of remdesivir equates to $2,340
per patient.
South Korea has been battling small but steady outbreaks of the new coronavirus,
with 51 new cases reported as of Tuesday, bringing the country's total to 12,850
cases with 282 deaths.
(Reporting by Sangmi Cha; Editing by Miyoung Kim and Edwina Gibbs)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
